A Phase 1 interventional study of MK-4082 and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) of the study medicine that can be used in future studies.
The goals of this study are to learn about:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 1.
Drug: MK-4082 · Drug: Placebo
Participants receive escalating doses of oral MK-4082 QD or a dose-matched placebo to reach maintenance dose 2.
Drug: MK-4082 · Drug: Placebo
Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 3.
Drug: MK-4082 · Drug: Placebo
Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 4.
Drug: MK-4082 · Drug: Placebo
Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 5.
Drug: MK-4082 · Drug: Placebo
Oral Tablet
Oral Tablet
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 98 Days
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 84 Days
Area Under the Curve from Time 0 to 24 hours (AUC0-24) of MK-4082
Blood samples will be collected to determine the AUC0-24hr of MK-4082.
Time frame: At designated timepoints (up to 24 hours postdose)
Time to Maximum Plasma Concentration (Tmax) of MK-4082
Blood samples will be collected to determine the Tmax of MK-4082.
Time frame: Predose and at designated timepoints up to 84 Days postdose
Maximum Plasma Concentration (Cmax) of MK-4082
Blood samples will be collected to determine the Cmax of MK-4082.
Time frame: Predose and at designated timepoints up to 84 Days postdose
Plasma Concentration at 24 Hours (C24) of MK-4082
Blood samples will be collected to determine the C24 of MK-4082.
Time frame: At designated timepoints up to 24 hours postdose
Area Under the Curve from Time 0 to Infinity (AUC0-Inf) of MK-4082
Blood samples will be collected to determine the AUC0-Inf of MK-4082.
Time frame: Predose and at designated timepoints up to 84 Days postdose
Area Under the Curve from Time 0 to Last (AUC0-Last) of MK-4082
Blood samples will be collected to determine the AUC0-last of MK-4082.
Time frame: Predose and at designated timepoints up to 84 Days postdose
Apparent Clearance (CL/F) of MK-4082
Blood samples will be collected to determine the CL/F of MK-4082.
Time frame: Predose and at designated timepoints up to 84 Days postdose
Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-4082
Blood samples will be collected to determine the Vz/F of MK-4082.
Time frame: Predose and at designated timepoints up to 84 Days postdose
Apparent Terminal Half-life (t1/2) of MK-4082
Blood samples will be collected to determine the t1/2of MK-4082.
Time frame: Predose and at designated timepoints up to 84 Days postdose
Change from Baseline in Body Weight
Change from baseline in body weight will be reported.
Time frame: Baseline and up to approximately 84 Days
Change from Baseline in Body Mass Index (BMI)
Change from baseline in body mass index (BMI) will be reported.
Time frame: Baseline and up to approximately 84 Days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2026 to primary completion in Sep 2026, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-4082